By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > Markets > Iveric Bio Agrees to $5.9 Billion Bid From Astellas. The Stock Is Surging.
Markets

Iveric Bio Agrees to $5.9 Billion Bid From Astellas. The Stock Is Surging.

News Room
Last updated: 2023/05/01 at 1:32 PM
By News Room
Share
2 Min Read
SHARE

Astellas Pharma
said Monday that it agreed to acquire Iveric Bio for around $5.9 billion. It’s the largest ever acquisition for Japan’s Astellas, underlining competition for acquisitions in growth areas such as ophthalmology. 

Biopharmaceuticals have been a relatively busy area for deals this year compared with a general slowdown in mergers and acquisitions in the U.S. 

Astellas
(ticker: 4503.Japan) said
Iveric
(ISEE) has promising programs and capabilities in the field of ophthalmology, including a potential treatment for geographic atrophy, an advanced form of age-related macular degeneration. 

Astellas also said the deal would provide future revenue which would help compensate for the expected decline in sales of its Xtandi prostate-cancer drug later this decade, due to the expiration of its patent.

Astellas said it would pay $40 a share for Iveric. Shares in Iveric were up 18% at $38.79 in premarket trading on Monday. Astellas shares closed up 2.2% in Japan. 

“The opportunity to create a world-class entity with the ophthalmology expertise and capabilities of Iveric Bio and the global reach and resources of Astellas is unique and has the potential to benefit patients worldwide suffering from blinding retinal diseases,” Iveric President Pravin Dugel said in a joint statement from the companies.

Write to Adam Clark at [email protected]

Read the full article here

News Room May 1, 2023 May 1, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Bank CEOs to warn lawmakers against proposal to boost capital

The CEOs of America’s top banks are on Wednesday expected to speak…

Vladimir Putin praises relations with UAE on first stop of Gulf tour 

Stay informed with free updatesSimply sign up to the Middle Eastern politics…

How to Use Options to Get ‘Conditional Dividends’

Tyros and market idiots, of which there are an unlimited, replenishing number,…

UK watchdog bans adverts by three airlines over ‘misleading’ environmental claims

Stay informed with free updatesSimply sign up to the Airlines myFT Digest…

Camel cigarette maker to take $31.5 billion write-down

British American Tobacco shares slumped 8% as the cigarette maker said it…

- Advertisement -
Ad imageAd image

You Might Also Like

Markets

With Little Revenue Expected, Cybertruck Could Dunk Tesla Stock

By News Room
Crypto

Solana’s BONK Token Hits Record High Amid Crypto Surge

By News Room
Stocks

Earnings call: Perimeter Solutions reports Q3 2023 earnings, addresses mild fire season impact and inventory destocking

By News Room
Markets

The 2024 Financial Landscape Is All About the Fed

By News Room
Crypto

Qatar’s Sovereign Wealth Fund Dives into Bitcoin with Potential $500B Investment – Confirmed News or Just Rumors?

By News Room
Stocks

Earnings call: Bioventus Inc. reports third quarter earnings, outperforms expectations, and raises annual guidance

By News Room
Markets

How To Collect Big Yields With Less Heartburn

By News Room
Crypto

Solana DeFi Platform Jupiter Shares Airdrop Allocations – Here’s How to Check Eligibility

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?